Actively Recruiting
EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms
Led by European Institute of Oncology · Updated on 2025-01-21
130
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
E
European Institute of Oncology
Lead Sponsor
A
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Collaborating Sponsor
AI-Summary
What this Trial Is About
For GEP mixed neuroendocrine (NE) non-neuroendocrine neoplasms (MiNENs) a key issue affecting prognosis is sometimes the difficulty in obtaining a timely diagnosis, as the NE component is often localized in deeper anatomical locations and/or becomes prevalent over time. The tissue material of biopsies may be not enough to define the NE component when this is particularly small and this could impact on therapeutic decision. Furthermore GEP NENs need to be characterized for potentially druggable biomarkers and liquid biopsy has clear advantage to the solid one to this aim. Here, we will exploit epigenetic differences characterizing NE tumors to build a DNA methylation-based liquid biopsy assay able to detect circulating tumor DNA of NE derivation, to enable the non-invasive diagnosis and monitoring of GEP-MiNENs.
CONDITIONS
Official Title
EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with histologically confirmed diagnosis of NEC/MINEN amenable to surgery with radical intent
- Patient with histologically confirmed diagnosis of NET amenable to surgery with radical intent
- Patient with metastatic NET/NEC, amenable to biopsy or surgery, including palliative intent
- Patient histologically confirmed non-NEN histotype including colorectal carcinoma, small intestine carcinoma, gastric or oesophageal carcinoma, pancreatic ductal adenocarcinoma, or metastasectomy from any non-NEN GI carcinoma
You will not qualify if you...
- Grading G1 and G2 with \u226410% Ki67
- Presence of concomitant neoplasm within 3 years
- Concomitant major haematological alteration
- Concomitant major organ dysfunction such as grade 3 or 4 liver or kidney failure
- Ongoing chemotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
European Institute of Oncology
Milan, Italy, 20141
Actively Recruiting
Research Team
N
Nicola Fazio, MD
CONTACT
F
Francesca Spada, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here